Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME AXETIL versus FORTAZ IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME AXETIL versus FORTAZ IN PLASTIC CONTAINER.
CEFUROXIME AXETIL vs FORTAZ IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime axetil is a prodrug that is hydrolyzed to cefuroxime, a second-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, thereby disrupting peptidoglycan cross-linking and leading to cell lysis. It is a third-generation cephalosporin with broad-spectrum activity against Gram-negative bacteria, including Pseudomonas aeruginosa.
250–500 mg orally twice daily; for severe infections (e.g., pneumonia), 500 mg twice daily; for uncomplicated urinary tract infections, 250 mg twice daily; for Lyme disease, 500 mg twice daily for 20 days.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
None Documented
None Documented
1.2-1.6 hours (normal renal function); prolonged to 15-22 hours in end-stage renal disease (CrCl <10 mL/min). For oral cefuroxime axetil, consider absorption and conversion to active cefuroxime.
1.8 hours in normal adults; prolonged to 3-5 hours in neonates and 10-30 hours in severe renal impairment (CrCl <10 mL/min)
Renal: 70-90% unchanged by glomerular filtration and tubular secretion; biliary/fecal: <10%
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; minor biliary/fecal (<10%)
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic